Insilico Medicine Leverages AI To Synthesize And Validate New Drug In Just 46 Days

Insilico Medicine Leverages AI To Synthesize And Validated New Drug In Just 46 Days

By  

Researchers have developed a new AI system which was able to discover and then successfully test several new compounds within 46 days.

A company developing artificial intelligence (AI) for drug discovery has published a paper describing how an AI system designed six novel inhibitors of DDR1, a kinase target implicated in fibrosis and other diseases, in 21 days.

Insilico Medicine, US, who conducted the study, developed the Generative Tensorial Reinforcement Learning (GENTRL) AI. Four of the compounds were found to be active in biochemical assays and two were validated in cell-based assays. One lead candidate was tested and demonstrated favourable pharmacokinetics in mice.

After the design stage, GENTRL was able to synthesise and pre-clinically validate the drug in 25 days, making the whole process take 46 days. According to the research team, the method is 15 times faster than a typical pharma company’s efficient R&D process.

“Now, this technology is going mainstream and we are happy to see the models developed a few years ago producing molecules against simpler targets and being validated experimentally in animals. When integrated into comprehensive drug discovery pipelines, these models work for many target classes and we work with the leading biotechnology companies to push the limits of generative chemistry and generative biology even further,” said Dr Alex Zhavoronkov, the founder and CEO of Insilico Medicine, the lead author of the study.

The results were published in Nature Biotechnology.